Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities

Full text
Author(s):
Victorino, Daniella Balduino [1] ; Nejm, Mariana [1] ; Guimaraes-Marques, Marcia [1] ; Scorza, Fulvio Alexandre [1] ; Scorza, Carla Alessandra [1]
Total Authors: 5
Affiliation:
[1] Univ Fed Sao Paulo, Paulista Med Sch, Dept Neurol & Neurosurg, Discipline Neurosci, Pedro Toledo 669, 1st Floor, BR-04039032 Sao Paulo, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: PHARMACEUTICAL MEDICINE; v. 35, n. 1 JAN 2021.
Web of Science Citations: 0
Abstract

The global burden of chronic disorders such as Parkinson's disease (PD) has rapidly increased over recent decades. Despite an increasing understanding of PD pathophysiology, there are no effective therapies capable of stopping or slowing the progression of this neurological condition. It has been suggested that type 2 diabetes mellitus (T2DM) may be a risk factor for PD and comorbid T2DM may worsen PD symptoms, as well as accelerate neurodegeneration. In fact, the similar pathological mechanisms shared by PD and T2DM have inspired several studies on the therapeutic potential of T2DM drugs against PD, among which glucagon-like peptide-1 receptor (GLP-1R) agonists are promising candidates. Here, we highlight the mechanisms linking T2DM and PD, as well as the links between insulin resistance (IR) and PD patients' risk of developing cognitive deficits. We also briefly review the effects of GLP-1R agonists on PD and discuss how the successful use of these substances in preclinical models of PD has paved the way for PD clinical trials. We further discuss how recent evidence on the beneficial effects of dulaglutide on cognitive function of T2DM patients may have important implications for PD drug repurposing. (AU)

FAPESP's process: 16/17746-3 - Evaluation of the effects of benzodiazepines on the in vivo electrophysiological activity of the brain and in vitro neuronal viability in the Ts65Dn mouse model
Grantee:Daniella Balduino Victorino
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 18/18568-7 - Sleep deprivation and possible heart changes in a model of Parkinson Disease induced by 6-Hydroxidopamine in rats: understanding for Sudden Death in Parkinson's Disease (SUDPAR).
Grantee:Fulvio Alexandre Scorza
Support Opportunities: Regular Research Grants